Advertisement
Canada markets close in 2 hours 41 minutes

  • S&P/TSX

    21,694.72
    -45.48 (-0.21%)
     

  • S&P 500

    5,063.95
    +2.13 (+0.04%)
     

  • DOW

    37,878.24
    +143.13 (+0.38%)
     

  • CAD/USD

    0.7235
    -0.0018 (-0.25%)
     

  • CRUDE OIL

    85.26
    -0.15 (-0.18%)
     

  • Bitcoin CAD

    87,046.30
    -2,144.03 (-2.40%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,410.30
    +27.30 (+1.15%)
     

  • RUSSELL 2000

    1,969.05
    -6.66 (-0.34%)
     

  • 10-Yr Bond

    4.6700
    +0.0420 (+0.91%)
     

  • NASDAQ

    15,905.83
    +20.81 (+0.13%)
     

  • VOLATILITY

    18.56
    -0.67 (-3.48%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6808
    -0.0016 (-0.23%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AS COMPANY EARNINGS ROLL IN

Shares of Live Nation, parent company of Ticketmaster, fall on antitrust probe report

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Business Wire
·1 min read

BURLINGAME, Calif., June 06, 2023--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12th, 2023 at 2:00 p.m. Pacific Time.

The presentation will be webcast and can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.

About Innoviva

Innoviva, Inc., is a diversified holding company with a portfolio of royalties and other healthcare assets, including Innoviva Specialty Therapeutics, a subsidiary focused on delivering innovative therapies in critical care and infectious disease. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, FF/VI) and ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. For more information on Innoviva, please visit here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005949/en/

Contacts

Investors & Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com